Journal ArticleDOI
Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients.
Audrey Vallée,Marie Marcq,A. Bizieux,Claude El Kouri,Herve Lacroix,Jaafar Bennouna,Jean-Yves Douillard,Marc G. Denis +7 more
Reads0
Chats0
About:
This article is published in Lung Cancer.The article was published on 2013-11-01. It has received 74 citations till now. The article focuses on the topics: Circulating Cell-Free DNA & Tumor-Derived.read more
Citations
More filters
Journal ArticleDOI
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress,Roz Brant,T. Hedley Carr,Simon Dearden,Suzanne Jenkins,Helen Brown,Tracey Hammett,Mireille Cantarini,J. Carl Barrett +8 more
TL;DR: The cobas(®) EGFR Mutation Test and BEAMing dPCR demonstrate a high sensitivity for T790M mutation detection, and these data support the use of both platforms in the AZD9291 clinical development program.
Journal ArticleDOI
Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
Sébastien Couraud,Felipe Vaca-Paniagua,Felipe Vaca-Paniagua,Stephanie Villar,Javier Oliver,Tibor Schuster,Tibor Schuster,Hélène Blanché,Nicolas Girard,Jean Trédaniel,Laurent Guilleminault,Radj Gervais,Nathalie Prim,Michel Vincent,Jacques Margery,Sébastien Larivé,Pascal Foucher,Bernard Duvert,Maxime Vallée,Florence Le Calvez-Kelm,James McKay,P. Missy,Franck Morin,Gérard Zalcman,Magali Olivier,Pierre-Jean Souquet +25 more
TL;DR: Next-generation sequencing on circulating free DNA samples obtained from a consecutive series of patients for the screening of a range of clinically relevant mutations demonstrates the feasibility and potential utility of mutation screening in cfDNA using IonTorrent NGS for the detection of arange of tumor biomarkers in patients with metastatic lung cancer.
Journal ArticleDOI
Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?
Marius Ilie,Véronique Hofman,Elodie Long,Olivier Bordone,Eric Selva,Kevin Washetine,Charles-Hugo Marquette,Paul Hofman +7 more
TL;DR: The main advances in the field of CTC and ctDNA detection in NSCLC patients are described and the main advantages and disadvantages of these two approaches are compared.
Journal ArticleDOI
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.
Antonio Marchetti,John F. Palma,Lara Felicioni,Tommaso De Pas,Rita Chiari,Maela Del Grammastro,Giampaolo Filice,Vienna Ludovini,Alba A. Brandes,Antonio Chella,Francesco Malorgio,Flavio Guglielmi,Michele De Tursi,Armando Santoro,Lucio Crinò,Fiamma Buttitta +15 more
TL;DR: This is the first study showing a strong correlation between the EGFR SQI in the first days of treatment and clinical response with relevant implications for patient management and a standardized PCR test is feasible.
Journal ArticleDOI
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
TL;DR: It is demonstrated that successful ctDNA recovery for mutation detection in NSCLC is dependent on pre- Analytical steps and development of standardised methods for the detection of KRAS mutations from ct DNA specimens is recommended to minimise the impact of pre-analytical steps on mutation detection rates.
References
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Cell-free nucleic acids as biomarkers in cancer patients
TL;DR: Findings are discussed with a specific focus on the clinical utility of cell-free nucleic acids as blood biomarkers for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies.
Journal ArticleDOI
Circulating cell free DNA: Preanalytical considerations.
Safia El Messaoudi,Safia El Messaoudi,Fanny Rolet,Florent Mouliere,Alain R. Thierry,Alain R. Thierry +5 more
TL;DR: This review examines the preanalytical parameters potentially affecting ccfDNA concentration and fragmentation at each pre Analytical step from blood drawing to the storage of c cfDNA extracts and determined the optimal preanalytic protocols for ccf DNA analysis.
Journal ArticleDOI
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Elizabeth Punnoose,Siminder K. Atwal,Weiqun Liu,Rajiv Raja,Bernard M. Fine,Brett G.M. Hughes,Rodney J. Hicks,Garret M. Hampton,Lukas C. Amler,Andrea Pirzkall,Mark R. Lackner +10 more
TL;DR: Evidence of a correlation between decreases in CTC counts and radiographic response by either FDG-PET or RECIST in patients with advanced NSCLC is provided and a potential role for using CTC decreases as an early indication of response to therapy and ctDNA for real-time assessment of mutation status from blood is suggested.
Related Papers (5)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more